54 Chapter 3 Predicting duration of WW In univariable analyses, patients with above-median [18F]FDG gm SUV max showed a shorter WWperiod compared with patients with below-median [18F]FDG gm SUV max (9.0 vs. 36.2 months, HR 5.6; 95%CI 2.4-14.7, p<0.001, Figure 4A). This was also observed - to a lesser extent - when [18F]FDG-uptake was expressed as MTV or TLG (Table 2A). The median WW-period of patients with above-median [89Zr]Zr-DFO-girentuximab gm SUV max was 9.3 months versus 21.3 months in patients with below-median uptake (HR 1.7; 95%CI 0.9-3.3, p= 0.13, Figure 4B). A B Figure 4. Kaplan Meier curve Figure 4A shows the Kaplan Meier curves for time on WW according to above or below median [18F]FDG uptake at baseline, with a median time under WW of 36.2 vs. 9.0 months.. Figure 4B shows the Kaplan Meier curves for time on WW according to above or below median [89Zr]Zr-DFO-girentuximab uptake at baseline, with a median time under WW of 21.3 vs. 9.3 months. In both figures, the per-patient uptake is expressed as the geometric mean SUVmax of all RECIST measurable PET-positive lesions. The yellow graph depicts patients with below-median tracer-uptake; the blue graph patients with above median tracer-uptake. *One patient was censored due to surgical excision of all tumor lesions
RkJQdWJsaXNoZXIy MTk4NDMw